全文获取类型
收费全文 | 386篇 |
免费 | 18篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 10篇 |
妇产科学 | 4篇 |
基础医学 | 53篇 |
口腔科学 | 12篇 |
临床医学 | 21篇 |
内科学 | 86篇 |
皮肤病学 | 21篇 |
神经病学 | 11篇 |
特种医学 | 68篇 |
外科学 | 36篇 |
综合类 | 10篇 |
预防医学 | 5篇 |
眼科学 | 9篇 |
药学 | 45篇 |
中国医学 | 3篇 |
肿瘤学 | 22篇 |
出版年
2021年 | 3篇 |
2020年 | 7篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 6篇 |
2016年 | 5篇 |
2015年 | 5篇 |
2014年 | 8篇 |
2013年 | 11篇 |
2012年 | 11篇 |
2011年 | 9篇 |
2010年 | 19篇 |
2009年 | 21篇 |
2008年 | 6篇 |
2007年 | 11篇 |
2006年 | 17篇 |
2005年 | 11篇 |
2004年 | 13篇 |
2003年 | 11篇 |
2002年 | 8篇 |
2001年 | 12篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 22篇 |
1997年 | 16篇 |
1996年 | 20篇 |
1995年 | 16篇 |
1994年 | 12篇 |
1993年 | 10篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 15篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 12篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有418条查询结果,搜索用时 15 毫秒
91.
Christopher Little Richard Szydlo TC Aw Mike Laffan Deepa R. J. Arachchillage 《British journal of haematology》2020,190(2):284-293
In this retrospective, single-centre, observational study, we assessed (i) use of anticoagulant and antiplatelet (AP) therapy, (ii) the duration of direct-acting oral anticoagulant (DOAC) discontinuation, (iii) renal function and (iv) PT and APTT as predictors of bleeding and blood product usage; in adults (>18 years) undergoing major cardiac surgery from 01.01.2015 to 31.12.2018. Comparisons were made between each treatment group (warfarin, DOAC and DOAC + AP) and untreated controls, and between warfarin and DOAC. A total of 2928 patients were included for analysis. Median (range) of DOAC discontinuation prior to surgery was five days (1–22) for DOAC and five days (2–7) for DOAC + AP. There were no differences in bleeding between anticoagulant groups versus control, or DOAC versus warfarin. There were no differences in blood product use between DOAC and warfarin patients. The duration of DOAC discontinuation but not the creatinine clearance influenced bleeding and blood products use. Thrombosis occurred in 0·7% and 3·1% in controls and patients on warfarin respectively (P = 0·099) with none among patients on DOAC or DOAC + AP. The PT/APTT had no predictive value. Median five-day discontinuation of DOAC +/− AP irrespective of renal function prevents an increase in bleeding compared to patients on warfarin or controls with no increase in thrombosis. 相似文献
92.
93.
Jessica Stahl Michael Braun Joerg Siebert Manfred Kietzmann 《International wound journal》2010,7(1):62-69
A combination of 0.1% octenidine dihydrochloride and 2% 2‐phenoxyethanol (octenisept®) is a commonly used disinfectant in human medicine. As porcine skin represents an adequate model for human skin, the effect of octenidine dihydrochloride and phenoxyethanol on wound healing is studied in pigs. Furthermore, the in vitro percutaneous permeation of the test substances is studied. The impact of the test formulations on wound healing is examined (A) under non occlusive conditions and (B) in comparison to another disinfectant based on povidone‐iodine under occlusive conditions, while wounds are treated daily with the test substances. The percutaneous permeation of octenidine dihydrochloride and phenoxyethanol is studied in Franz‐type diffusion cells with intact skin as well as barrier disrupted after tape stripping. Compared with povidone‐iodine or vehicle treatment as well as untreated control wounds the treatment of wounds with the test formulation has no influence on the healing rate in pigs and does not induce retardation of wound healing. The in vitro diffusion experiment reveals that octenidine dihydrochloride is only detectable in the acceptor chamber of three‐barrier disrupted skin samples. Phenoxyethanol permeates through intact porcine skin in amounts of 11.3% and through barrier disrupted skin in amounts of 43.9% 相似文献
94.
95.
Nodular lymphocyte predominance Hodgkin's disease: a monoclonal or polyclonal B-cell disorder? 总被引:3,自引:0,他引:3
Nodular lymphocyte predominance Hodgkin's disease (NLPHD) is characterized by the presence of atypical putatively neoplastic cells (L & H cells) with a B-cell phenotype. A proportion of patients with NLPHD develop a simultaneous or subsequent large cell B lymphoma (LCL) that is thought to evolve directly from the L & H cells of NLPHD. However, the clonal nature of L & H cells remains controversial, and the relationship between NLPHD and complicating LCL has not been fully established. In an attempt to determine the clonality of L & H cells and to clarify the link between NLPHD and complicating LCL, we used polymerase chain reaction (PCR) to analyze 33 cases of NLPHD, including 15 cases with simultaneous or subsequent LCL, for clonal immunoglobulin (lg) heavy chain variable region (VH) gene rearrangements. PCR amplifications with consensus primers covering framework 2 or framework 3 to joining region were performed on paraffin-embedded tissue sections and, in 12 cases, on microdissection-enriched L & H cells. No clonal Ig rearrangements were detected. In eight of the 15 LCL, monoclonal IgVH regions were amplified, four of which were cloned and sequenced. Clone specific primers were designed based on the unique N region sequences. These allowed detection of LCL clones at a sensitivity up to 1,000 times greater than the consensus primers, as determined by dilution assays. However, no LCL clones were detected in the preceding NLPHD, including microdissection-enriched L & H cells. Our results suggest that populations of L & H cells do not carry monoclonal Ig rearrangements and provide no evidence for a clonal link between NLPHD and complicating LCL. 相似文献
96.
整合蛋白α5亚基表达与肝癌恶性表型 总被引:3,自引:0,他引:3
目的探讨整合蛋白α5亚基与原发性肝癌的关系。方法应用免疫组化技术(ABC法)和Northernblot杂交检测整合蛋白α5亚基在原发性肝癌中的表达。结果发现在79例癌与癌周组织α5阳性率分别为32.9%和81.0%,两者间差异有显著性(P<0.01)。直径≤5cm的肝癌α5阳性率高于直径>10cm的肝癌(55.6%比10.0%,P<0.01),分化较好的肝癌α5阳性率高于分化不良者(40.6%比16.0%,P<0.05),已发生明确肝内转移(包括肝内播散和门静脉癌栓形成)的肝癌α5阳性率低于未发生肝内转移者(20.6%比42.2%,P<0.05)。α5亚基表达与患者年龄、血清甲胎蛋白水平、乙型肝炎病毒感染、肝硬化有无等因素均无明显相关(P>0.05)。Northernblot杂交结果也同时显示,非侵袭性肝癌α5表达高于侵袭性肝癌。结论整合蛋白α5低表达与肝癌增大、分化程度低、侵袭转移发生等恶性表型相关,可能对这些恶性表型起负性调节作用。 相似文献
97.
Activation of factor X by both the unactivated tissue factor:factor VII complex (TF:VII) and the activated tissue factor:factor VIIa complex (TF:VIIa) has been studied in the presence of tissue factor pathway inhibitor (TFPI), antithrombin III (ATIII), and heparin. At near-plasma concentrations of TFPI, ATIII, and factor X, factor X activation that occurs in response to TF:VII is essentially abolished in the presence of heparin (0.5 micromol/L). This effect requires both inhibitors, acting on different targets: (1) ATIII, which in the presence of heparin blocks the activation of TF:VII, and (2) TFPI, which inhibits the TF:VIIa that is generated. In the absence of ATIII, TFPI alone with heparin reduces but does not abolish factor X activation. Conversely, in the absence of TFPI, ATIII + heparin reduces but does not abolish TF:VIIa generation and allows continuing activation of factor X. These results indicated that when the unactivated TF:VII complex is the initiating stimulus, heparin-dependent reduction in the rate and extent of factor X activation requires both ATIII and TFPI. In contrast, if TF:VIIa is used to initiate activation, only TFPI is involved in its regulation. 相似文献
98.
Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin 总被引:7,自引:0,他引:7
Cooke CB; Krenacs L; Stetler-Stevenson M; Greiner TC; Raffeld M; Kingma DW; Abruzzo L; Frantz C; Kaviani M; Jaffe ES 《Blood》1996,88(11):4265-4274
We identified eight cases of T-cell lymphoma with evidence of a gamma delta phenotype over a 13-year period. Seven of these cases conformed to a distinct clinicopathologic entity of hepatosplenic gamma delta T- cell lymphoma. Nearly all of these patients were young adult males (five of seven), with a median age at presentation of 20 years. They presented with marked hepatosplenomegaly, without lymphadenopathy or significant peripheral blood lymphocytosis. Thrombocytopenia was seen in all patients, and five of seven were mildly anemic. The clinical course was aggressive, and despite multiagent chemotherapy, the median survival duration was less than 1 year. The morphologic findings were uniform; a monomorphic population of medium-sized lymphoid cells with moderately clumped chromatin and a rim of pale cytoplasm infiltrated the sinusoids of the spleen, liver, and bone marrow. The cells had a characteristic immunophenotype: CD2+, CD3+, CD4-, CD5-, CD7+, CD16+, CD57-, CD25-, T-cell receptor (TCR)delta +, beta F1-. CD8 was positive in four of seven cases tested, and CD56 was positive in five of six. All cases expressed the cytotoxic granule-associated protein, TIA1, but perforin was detected in only one case. All cases with assessable DNA had a TCR gamma gene rearrangement, and lacked Epstein-Barr virus sequences. Isochromosome 7q was identified in two cases with cytogenetic information. The one case of cutaneous gamma delta T-cell lymphoma differed in its clinical manifestations, histologic appearance, and immunophenotype. We conclude that hepatosplenic gamma delta T-cell lymphoma is a distinct clinicopathologic entity derived from cytotoxic gamma delta T cells, and should be distinguished from other lymphomas of T-cell and natural-killer cell (NK)-like T-cell derivation. 相似文献
99.
DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment 总被引:2,自引:1,他引:2
Yu C; Storb R; Mathey B; Deeg HJ; Schuening FG; Graham TC; Seidel K; Burnett R; Wagner JL; Shulman H 《Blood》1995,86(11):4376-4381
Previous studies found that marrow allografts from DLA-identical littermates resulted in survival of 60% of recipient dogs after an otherwise lethal dose of 450 cGy of total body irradiation (TBI), either because of successful allografts or autologous recovery after rejection of the allografts. Forty percent of dogs died with marrow aplasia after allograft rejection. The current study asked whether allogeneic engraftment could be enhanced and survival improved by treating allograft recipients with high doses of corticosteroids or with cyclosporine (CSP), administered either before or after transplantation. Five dogs in group 1 received corticosteroids beginning on day -5 and ending on day 32 after transplant. The starting dose was 12.5 mg of prednisone per kilogram orally twice daily. All five dogs rejected their allografts; three died early with marrow aplasia and two showed endogenous marrow recovery. Nine dogs received CSP from day -6 to day -1 before transplantation at a dose of 20 mg/kg/d intravenously administered in divided doses. All nine dogs rejected the marrow allograft; six died with marrow aplasia and three survived with endogenous marrow recovery. Seven dogs received CSP after transplantation at a dose of 30 mg/kg/d orally from day -1 to day 35. All seven had sustained allografts (two mixed chimeras and five complete donor-type chimeras) and became healthy long-term survivors without graft-versus-host disease. These results extend previous observations and confirm that grafts of marrow from DLA-identical littermates improved survival of dogs exposed to low but otherwise lethal doses of TBI. Additional therapy with high-dose corticosteroids administered peritransplantation and posttransplantation or CSP administered before transplantation neither enhanced the rate of allogeneic engraftment nor improved survival; however, CSP administered after transplantation resulted in successful allografts and event-free survival in all cases. 相似文献
100.
Nash RA; Schuening FG; Seidel K; Appelbaum FR; Boone T; Deeg HJ; Graham TC; Hackman R; Sullivan-Pepe M; Storb R 《Blood》1994,83(7):1963-1970
Recombinant canine granulocyte-macrophage colony-stimulating factor (rcGM-CSF) was studied in normal dogs and in dogs receiving otherwise lethal total body irradiation (TBI) without marrow transplant. Five normal dogs receiving 25 micrograms/kg of rcGM-CSF by subcutaneous (SC) injection twice daily (BID) for 14 days showed increases in peripheral blood neutrophil counts of three to five times the baseline. Platelet counts decreased during administration of rcGM-CSF to a mean nadir of 52,800. Ten dogs received 400 cGy TBI at 10 cGy/min from two opposing 60Co sources and no marrow graft. Within 2 hours of TBI, rcGM-CSF was begun at a dose of 50 micrograms/kg SC BID for 5 doses and then continued at 25 micrograms/kg SC BID for 21 days. Only 1 of the 10 dogs receiving rcGM-CSF survived with complete and sustained recovery of hematopoiesis. One of 13 historical control dogs survived after 400 cGy with no hematopoietic growth factor or marrow infusion. Results with rcGM-CSF were compared with previous and concurrent data with G-CSF studied in the same model. Of 10 dogs receiving G-CSF, 8 survived with complete and sustained hematopoietic recovery, a significantly better survival than that seen with rcGM-CSF (P = .006). Neutrophil counts were sustained at higher levels after TBI for the first 18 days in the G-CSF group (P < .016) and the neutrophil nadirs were higher. No differences in neutrophil nadirs were noted between the rcGM-CSF and control groups. Dogs treated with rcGM-CSF experienced a more rapid decline of platelet counts than G-CSF-treated or control dogs over the first 18 days (P < .001). The nadir of the platelet count was higher in the control group than in either the G-CSF or rcGM-CSF group and no significant difference was observed between the G-CSF and rcGM-CSF groups. After otherwise lethal TBI (400 cGy) in dogs, rcGM-CSF was not effective in promoting hematopoietic recovery or improving survival. 相似文献